{
    "clinical_study": {
        "@rank": "131059", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose Danazol", 
                "arm_group_type": "Experimental", 
                "description": "Low Dose Danazol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy of ultra low dose danazol (Optina) for the treatment\n      of diabetic macular edema versus placebo.  Optina has already been granted 505(b)2 status by\n      the FDA and will incorporate all safety data from prior FDA approvals.  Additional safety\n      data will be collected specifically for this low dosage.\n\n      A portion of 505(b)2 drugs are approved based on a single clinical trial."
        }, 
        "brief_title": "A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema", 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will evaluate the efficacy of ultra low dose danazol (Optina) for the treatment\n      of diabetic macular edema versus placebo.  Optina has already been granted 505(b)2 status by\n      the FDA and will incorporate all safety data from prior FDA approvals.  Additional safety\n      data will be collected specifically for this low dosage.\n\n      A portion of 505(b)2 drugs are approved based on a single clinical trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 years or older with Type 1 or 2 diabetes mellitus (defined as a\n             self report of diabetes accompanied by treatment (insulin or diet) or a history of\n             fasting plasma glucose \u2265 7.0mmo/l (126 mg/dl) or 2-hr plasma glucose \u2265 11.1 mmo/1\n             (200 mg/dl)]\n\n          -  Stable diabetic and metabolic control (no major changes in diabetic or lipid reducing\n             medications for 3 months prior to start of this study as determined by the\n             Investigator)\n\n          -  Change in VA within previous 12 months reasonably believed to be associated with DME\n             in the opinion of the Investigator\n\n          -  BCVA in accordance with ETDRS letter score of \u2265 24 (e.g., 20/320 or better) and \u2264 78\n             (e.g., 20/32 or worse)\n\n          -  Definite retinal thickening \u2265 275 microns on spectral-domain OCT due to DME involving\n             the center of the macula on clinical exam in the opinion of the Investigator\n\n          -  Media clarity, pupillary dilation, and patient cooperation sufficient for adequate\n             fundus photographs\n\n          -  Assessment by the Investigator that focal photocoagulation can be deferred safely for\n             16 weeks\n\n        Exclusion Criteria:\n\n          -  Known allergy to any danazol (Cyclomen or Danocrine) or any other non-medicinal\n             component of the danazol test drug (cornstarch, lactose, magnesium stearate, gelatin,\n             and talc) (Note: Lactose intolerance is not a contraindication to ingesting the small\n             amount of lactose contained in oral medications)\n\n          -  History of systemic (e.g., oral intravenous, intramuscular, subcutaneous,\n             intrauterine, epidural, bursal, or implanted) androgens, progesterone or\n             corticosteroids (including topical ophthalmic corticosteroids preparations within 4\n             months prior to randomization (topical non-ophthalmic corticosteroids are not\n             excluded)\n\n          -  Blood pressure >160/90 mm Hg (in cases where either or both of the systolic or\n             diastolic limits are exceeded, blood pressure can be re-measured after 10 minutes\n             rest period for inclusion in the study)\n\n          -  HbA1c greater than 11%\n\n          -  Carcinoma of the breast\n\n          -  Unstable cardiovascular disease or a history of significant heart disease (including\n             unstable angina, acute coronary syndrome, myocardial infarction, or history of\n             coronary revascularization procedure) within 6 months before randomization\n\n          -  Macular edema considered to be due to a cause other than DME; e.g., cataract\n             extraction, vitreo-retinal interface disease (a taut posterior hyaloid or epiretinal\n             membrane)\n\n          -  An ocular condition is present such that, in the opinion of the Investigator, VA\n             would not improve from resolution of macular edema (e.g., foveal atrophy, closure of\n             juxafoveal capillaries, dense subfoveal hard exudates)\n\n          -  An ocular condition (other than diabetic retinopathy) that, in the opinion of the\n             Investigator, might affect macular edema or alter VA during the course of the study,\n             e.g. vein occlusion, uveitis or other ocular inflammatory disease, Irvine-Gass\n             Syndrome, etc.\n\n          -  History of treatment for DME at any time in the past 3 months (such as focal/grid\n             macular photocoagulation, intravitreal or peribulbar corticosteroids, anti-vascular\n             endothelial growth factor [VEGF drugs], or any other treatment\n\n          -  History of panretinal scatter photocoagulation (PRP) within 4 months prior to\n             randomization or anticipated need for PRP in the 6 months following randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821677", 
            "org_study_id": "AP-05-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Dose Danazol", 
                "intervention_name": "Low Dose Danazol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Danazol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 30, 2013", 
        "location": {
            "contact": {
                "email": "hloose@ampiopharma.com", 
                "last_name": "Holli Loose, MSc", 
                "phone": "720-437-6528"
            }, 
            "facility": {
                "address": {
                    "city": "Greenwood Village", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80111"
                }, 
                "name": "Holli Loose"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adult Patients With Diabetic Macular Edema", 
        "overall_contact": {
            "email": "hloose@ampiopharma.com", 
            "last_name": "Holli Loose, MSc", 
            "phone": "7204376528"
        }, 
        "overall_contact_backup": {
            "email": "vclift@ampiopharma.com", 
            "last_name": "Vaughan Clift, MD", 
            "phone": "7204376500"
        }, 
        "overall_official": {
            "affiliation": "Ampio Pharmaceuticals. Inc.", 
            "last_name": "Vaughan Clift, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement in Best Corrected Visual Acuity", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ampio Pharmaceuticals. Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ampio Pharmaceuticals. Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}